The Role of Antibody-Based Therapies in Neuro-Oncology

IF 3 Q3 IMMUNOLOGY

Antibodies Pub Date : 2023-11-13 DOI:10.3390/antib12040074

Rishab Ramapriyan, Jing Sun, Annabel Curry, Leland G. Richardson, Tarun Ramesh, Matthew A. Gaffey, Patrick C. Gedeon, Elizabeth R. Gerstner, William T. Curry, Bryan D. Choi

{"title":"The Role of Antibody-Based Therapies in Neuro-Oncology","authors":"Rishab Ramapriyan, Jing Sun, Annabel Curry, Leland G. Richardson, Tarun Ramesh, Matthew A. Gaffey, Patrick C. Gedeon, Elizabeth R. Gerstner, William T. Curry, Bryan D. Choi","doi":"10.3390/antib12040074","DOIUrl":null,"url":null,"abstract":"This review explores the evolving landscape of antibody-based therapies in neuro-oncology, in particular, immune checkpoint inhibitors and immunomodulatory antibodies. We discuss their mechanisms of action, blood-brain barrier (BBB) penetration, and experience in neuro-oncological conditions. Evidence from recent trials indicates that while these therapies can modulate the tumor immune microenvironment, their clinical benefits remain uncertain, largely due to challenges with BBB penetration and tumor-derived immunosuppression. This review also examines emerging targets such as TIGIT and LAG3, the potential of antibodies in modulating the myeloid compartment, and tumor-specific targets for monoclonal antibody therapy. We further delve into advanced strategies such as antibody–drug conjugates and bispecific T cell engagers. Lastly, we explore innovative techniques being investigated to enhance antibody delivery, including CAR T cell therapy. Despite current limitations, these therapies hold significant therapeutic potential for neuro-oncology. Future research should focus on optimizing antibody delivery to the CNS, identifying novel biological targets, and discovering combination therapies to address the hostile tumor microenvironment.","PeriodicalId":8188,"journal":{"name":"Antibodies","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibodies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/antib12040074","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This review explores the evolving landscape of antibody-based therapies in neuro-oncology, in particular, immune checkpoint inhibitors and immunomodulatory antibodies. We discuss their mechanisms of action, blood-brain barrier (BBB) penetration, and experience in neuro-oncological conditions. Evidence from recent trials indicates that while these therapies can modulate the tumor immune microenvironment, their clinical benefits remain uncertain, largely due to challenges with BBB penetration and tumor-derived immunosuppression. This review also examines emerging targets such as TIGIT and LAG3, the potential of antibodies in modulating the myeloid compartment, and tumor-specific targets for monoclonal antibody therapy. We further delve into advanced strategies such as antibody–drug conjugates and bispecific T cell engagers. Lastly, we explore innovative techniques being investigated to enhance antibody delivery, including CAR T cell therapy. Despite current limitations, these therapies hold significant therapeutic potential for neuro-oncology. Future research should focus on optimizing antibody delivery to the CNS, identifying novel biological targets, and discovering combination therapies to address the hostile tumor microenvironment.

查看原文本刊更多论文

基于抗体的治疗在神经肿瘤中的作用

这篇综述探讨了神经肿瘤学中基于抗体的治疗方法的发展前景，特别是免疫检查点抑制剂和免疫调节抗体。我们讨论了它们的作用机制，血脑屏障(BBB)渗透，以及在神经肿瘤条件下的经验。最近的试验证据表明，虽然这些疗法可以调节肿瘤免疫微环境，但其临床益处仍不确定，主要是由于血脑屏障渗透和肿瘤源性免疫抑制的挑战。本综述还研究了新兴靶点，如TIGIT和LAG3，抗体在调节髓系室中的潜力，以及单克隆抗体治疗的肿瘤特异性靶点。我们进一步钻研先进的策略，如抗体-药物偶联物和双特异性T细胞接合物。最后，我们探索正在研究的创新技术，以增强抗体传递，包括CAR - T细胞疗法。尽管目前存在局限性，但这些疗法在神经肿瘤学方面具有显著的治疗潜力。未来的研究应侧重于优化抗体递送到中枢神经系统，识别新的生物靶点，并发现联合治疗来解决敌对肿瘤微环境。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Antibodies IMMUNOLOGY-

CiteScore

7.10

自引率

6.40%

发文量

审稿时长

11 weeks

期刊介绍： Antibodies (ISSN 2073-4468), an international, peer-reviewed open access journal which provides an advanced forum for studies related to antibodies and antigens. It publishes reviews, research articles, communications and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. Full experimental and/or methodical details must be provided. Electronic files or software regarding the full details of the calculation and experimental procedure - if unable to be published in a normal way - can be deposited as supplementary material. This journal covers all topics related to antibodies and antigens, topics of interest include (but are not limited to): antibody-producing cells (including B cells), antibody structure and function, antibody-antigen interactions, Fc receptors, antibody manufacturing antibody engineering, antibody therapy, immunoassays, antibody diagnosis, tissue antigens, exogenous antigens, endogenous antigens, autoantigens, monoclonal antibodies, natural antibodies, humoral immune responses, immunoregulatory molecules.